- Home
- CHRS vs ETX Comparison
CHRS vs ETX Comparison
Compare CHRS & ETX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ETX
- Stock Information
- Founded
- CHRS 2010
- ETX 2005
- Country
- CHRS United States
- ETX United States
- Employees
- CHRS N/A
- ETX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ETX
- Sector
- CHRS Health Care
- ETX
- Exchange
- CHRS Nasdaq
- ETX NYSE
- Market Cap
- CHRS 185.5M
- ETX 199.8M
- IPO Year
- CHRS 2014
- ETX N/A
- Fundamental
- Price
- CHRS $1.52
- ETX $18.03
- Analyst Decision
- CHRS Strong Buy
- ETX
- Analyst Count
- CHRS 4
- ETX 0
- Target Price
- CHRS $5.38
- ETX N/A
- AVG Volume (30 Days)
- CHRS 10.1M
- ETX 32.7K
- Earning Date
- CHRS 11-06-2024
- ETX 01-01-0001
- Dividend Yield
- CHRS N/A
- ETX 4.20%
- EPS Growth
- CHRS N/A
- ETX N/A
- EPS
- CHRS N/A
- ETX N/A
- Revenue
- CHRS $304,340,000.00
- ETX N/A
- Revenue This Year
- CHRS $1.64
- ETX N/A
- Revenue Next Year
- CHRS $16.98
- ETX N/A
- P/E Ratio
- CHRS N/A
- ETX N/A
- Revenue Growth
- CHRS 44.19
- ETX N/A
- 52 Week Low
- CHRS $0.66
- ETX $16.36
- 52 Week High
- CHRS $3.70
- ETX $18.60
- Technical
- Relative Strength Index (RSI)
- CHRS 52.47
- ETX 34.37
- Support Level
- CHRS $1.45
- ETX $18.29
- Resistance Level
- CHRS $1.85
- ETX $18.08
- Average True Range (ATR)
- CHRS 0.23
- ETX 0.12
- MACD
- CHRS -0.03
- ETX -0.03
- Stochastic Oscillator
- CHRS 3.88
- ETX 10.45
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About ETX EATON VANCE MUNICIPAL INCOME 2028
Eaton Vance Municipal Income 2028 Term Trust is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The fund invests in various sectors such as a bond bank, education, housing, electric utilities, transportation, and others.